While there exists promising literature that indicates the potential of DPP-4 inhibitors to enhance neurite length in DRG neurons within type 1 diabetic rodent models by preventing neuropathy and IENFDs reduction [42,43,44,45], it remains ambiguous whether their efficacy stems solely from their hypoglycemic properties or if they exert a direct influence on the PNS. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.